Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital

GlobeNewswire May 4, 2020

KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

GlobeNewswire March 2, 2020

KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

GlobeNewswire February 28, 2020

Nasdaq Grants KemPharm's Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

GlobeNewswire January 15, 2020

KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

GlobeNewswire December 18, 2019

KemPharm Reports Third Quarter 2019 Results

GlobeNewswire November 14, 2019

KemPharm to Report Third Quarter 2019 Results

GlobeNewswire November 12, 2019

KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

GlobeNewswire October 31, 2019

KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

GlobeNewswire October 22, 2019

KemPharm Provides Updates Regarding its Board of Directors

GlobeNewswire September 20, 2019

KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

GlobeNewswire September 17, 2019

KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.

GlobeNewswire September 5, 2019

KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

GlobeNewswire September 4, 2019

KemPharm Reports Second Quarter 2019 Results

GlobeNewswire August 13, 2019

KemPharm Reports First Quarter 2019 Results

GlobeNewswire May 14, 2019

KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate

GlobeNewswire January 29, 2019

KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting

GlobeNewswire January 18, 2019

KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

GlobeNewswire January 7, 2019

New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire January 2, 2019

KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio

GlobeNewswire December 19, 2018